Effectiveness of using Glutamyl-cysteinyl-glycine disodium immunomodulator in patients with destructive multidrug-resistant tuberculosis of lungs

Authors

  • A. S. Shalmin
  • E. N. Raznatovskaya

DOI:

https://doi.org/10.14739/2409-2932.2015.2.45196

Keywords:

Immunomodulator, Multidrug-Resistant Tuberculosis

Abstract

Importance of the problem: treatment efficiency improving in patients with multidrug-resistant destructive pulmonary tuberculosis (MDR).

Aim. To study the complex treatment effectiveness in patients with destructive MDR with implementation of Glutamyl-cysteinyl-glycine disodium (GCGD) immunomodulator.

Methods and results. On the basis of standard chemotherapy course main treatment effectiveness parameters have been estimated of 30 patients who were treated with implementation of GCGD on the basis of standard chemotherapy course and 30 patients who were treated with standard chemotherapy course alone.

Conclusion. Complex treatment of patients with destructive MDR with implementation of GCGD immunomodulator on the basis of standard chemotherapy course for immunity state correction allows to increase effectiveness of treatment by 33,3%.  

References

Dmitriev, V. A. (2008) Global problem of tuberculosis and modern WHO strategy to combat it. Antibiotics and chemotherapy, 5-6, 3-6. [in Russian].

Cherenko, S. A. Problem multidrug-resistant tuberculosis tuberculosis. Access: http://www.ifp.kiev.ua/doc/ people / tubrezist.htm. [in Russian].

Feschenko, Y. I. (2011). Antibiotic resistance of microorganisms. State the problem and ways to solve. Ukrainian Pulmonology Journal, 4, 41-43. [in Russian].

Mishin, V. Yu., Komissarov, O. G., Chukanov, V. I. & Kononets, A. (2009). Peculiarities of the process and the effectiveness of the treatment of patients with pulmonary tuberculosis, Mycobacterium tuberculosis excreting with extensive drug resistance to anti-TB drugs. Problems of tuberculosis, 2, 50-52. [in Russian].

Platonov, I. L., Weaver, O. A., Sahelashvili, M. I., Schurko, G. V., Lapovets, N. E. & Shtybel, G. D. (2011). Evaluation of antimycobacterial therapy in patients with pulmonary tuberculosis on indicators of immunological research. Tuberculosis, pulmonary disease, HIV infection, 2, 21-25. [in Russian].

Chernushenko, E. F. & Protsiuk, R. G. (2010). Аntituberculous immunity (Part I). Ukrainian Pulmonology Journal, 4, 53-58. [in Russian].

Chernushenko, E. F. & Protsiuk, R. G. (2011). Аntituberculous immunity (Part II). Ukrainian Pulmonology Journal, 1, 29-32. [in Russian].

Feschenko, Yu. I., Yschuk, S. G. & Matvyenko, A. (2012). Therapeutic opportunities of innovative immunmodulator in pulmonology and phthisiology. Ukrainian Pulmonology Journal, 3, 50-54. [in Russian].

Balasanyants, G. S. & Sukhanov, D. S. (2011). Some aspects of pathogenetic therapy for tuberculosis in modern conditions. Therapeutic rchive, 8, 21-24. [in Russian].

Antushevich, A. E., Antonov, V. G., Vasilenko, K. P. & Burov, E. B. (2005). A possible mechanism for eliminating antibiotic resistance of Mycobacterium tuberculosis glutoxim. First All-Russian Scientific Forum "Innovative Technologies in Medicine XXI century": Collection mes, 405-407. [in Russian].

Peresi, E., Silva, S. M. & Calvi, S. A. (2008). Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis Jornal Brasileiro de Pneumologia, 11, 942-949.

Downloads

How to Cite

1.
Shalmin AS, Raznatovskaya EN. Effectiveness of using Glutamyl-cysteinyl-glycine disodium immunomodulator in patients with destructive multidrug-resistant tuberculosis of lungs. Current issues in pharmacy and medicine: science and practice [Internet]. 2015Jul.14 [cited 2024Dec.28];(2). Available from: http://pharmed.zsmu.edu.ua/article/view/45196

Issue

No. 2 (2015)

Section

Experimental and clinical pharmacology

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.     Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)